Randomised controlled trial of oxygen therapy and high-flow nasal therapy in African children with pneumonia

Autor: Kathryn Maitland, Florence Alaroker, Mainga Hamaluba, Charles Engoru, Abner Tagoola, H Mnjella, David A Harrison, John F. Fraser, Karen Thomas, Bandika, Sarah Kiguli, Thomas N. Williams, Peter Olupot-Olupot, William Okiror, E Oguda, Kathy Rowan, Robert O. Opoka, Ayub Mpoya, Eva Nabawanuka, Denis Aromut, Margeret Nakuya
Přispěvatelé: group, COAST trial, Medical Research Council (MRC), DFID/MRC/Wellcome Trust, European and Developing Countries Clinical Trials Partnership, Wellcome Trust
Rok vydání: 2021
Předmět:
medicine.medical_specialty
Original
medicine.medical_treatment
INFANTS
Critical Care and Intensive Care Medicine
1117 Public Health and Health Services
law.invention
03 medical and health sciences
0302 clinical medicine
Critical Care Medicine
Randomized controlled trial
High-flow nasal therapy
law
General & Internal Medicine
Oxygen therapy
Anesthesiology
Internal medicine
medicine
Clinical endpoint
Humans
Child
Hypoxia
Science & Technology
business.industry
MORTALITY
AIR
Mortality rate
Uncertainty
Oxygen Inhalation Therapy
1103 Clinical Sciences
030208 emergency & critical care medicine
Pneumonia
HYPOXEMIA
Odds ratio
COAST trial group
medicine.disease
Kenya
Emergency & Critical Care Medicine
respiratory tract diseases
Oxygen
Clinical trial
030228 respiratory system
African children
business
Life Sciences & Biomedicine
Zdroj: Intensive Care Medicine
ISSN: 1432-1238
0342-4642
Popis: Purpose The life-saving role of oxygen therapy in African children with severe pneumonia is not yet established. Methods The open-label fractional-factorial COAST trial randomised eligible Ugandan and Kenyan children aged > 28 days with severe pneumonia and severe hypoxaemia stratum (SpO2 3 h receipt of oxygen were excluded. The primary endpoint was 48 h mortality; secondary endpoints included mortality or neurocognitive sequelae at 28 days. Results The trial was stopped early after enrolling 1852/4200 children, including 388 in the severe hypoxaemia stratum (median 7 months; median SpO2 75%) randomised to HFNT (n = 194) or LFO (n = 194) and 1454 in the hypoxaemia stratum (median 9 months; median SpO2 88%) randomised to HFNT (n = 363) vs LFO (n = 364) vs permissive hypoxaemia (n = 727). Per-protocol 15% of patients in the permissive hypoxaemia group received oxygen (when SpO2
Databáze: OpenAIRE
Externí odkaz: